Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in the United States, disproportionately affecting African Americans. Aspirin is an effective, low cost option to reduce cardiovascular events. This study sought to describe the use of aspirin for CVD prevention in African Americans and evaluate associations with demographics, cardiovascular risk factors and health behaviors and beliefs. A total of 684 African Americans adults ages 45–79 years completed surveys and were included in this analysis. Proportions of aspirin use were stratified by primary and secondary prevention and by number of CVD risk factors in the primary prevention population. Logistic regression was used to evaluate associations with aspirin use. Secondary prevention aspirin use was 62%. Primary prevention aspirin use was 32% overall and increased to 54% in those with > 2 CVD risk factors. A history of diabetes [adjusted odds ratio (aOR) 3.42, 95% CI 2.18–5.35] and hypertension (aOR 2.25, 95% CI 1.39–3.65) were strongly associated with primary prevention aspirin use, but a conversation with a health care provider was even stronger (aOR 6.41, 95% CI 4.07–10.08). Participants who answered positively to statements about people similar to them taking aspirin or that close contacts think they should take aspirin, were much more likely to take aspirin (aOR 4.80; 95% CI 2.58–8.93 and aOR 7.45; 95% CI 4.70–11.79 respectively). These findings support a hypothesis that aspirin use may increase by encouraging conversations with health care providers and creating a supportive social environment for aspirin use. Further studies need to be done to test this hypothesis.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., et al. (2018). Heart disease and stroke statistics-2018 update: A report from the American Heart Association. Circulation, 137(12), e67–e492.
Mensah, G. A., Mokdad, A. H., Ford, E. S., Greenlund, K. J., & Croft, J. B. (2005). State of disparities in cardiovascular health in the United States. Circulation, 111(10), 1233–1241.
Sidney, S., Quesenberry, C. P., Jaffe, M. G., Sorel, M., Nguyen-Huynh, M. N., Kushi, L. H., et al. (2016). Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiology, 1(5), 594–599.
Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., et al. (2009). Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373(9678), 1849–1860.
Rothwell, P. M., Algra, A., Chen, Z., Diener, H. C., Norrving, B., & Mehta, Z. (2016). Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: Time-course analysis of randomised trials. Lancet, 388(10042), 365–375.
Luepker, R. V., Steffen, L. M., Duval, S., Zantek, N. D., Zhou, X., & Hirsch, A. T. (2015). Population trends in aspirin use for cardiovascular disease prevention 1980–2009: The Minnesota Heart Survey. Journal of the American Heart Association, 4(12), e002320.
Steering Committee of the Physicians’ Health Study Research Group*. (1989). Final report on the aspirin component of the ongoing Physicians’ Health Study. New England Journal of Medicine, 321(3), 129–135.
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., et al. (1998). Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 351(9118), 1755–1762.
Medical Research Council’s General Practice Research Framework. (1998). Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet, 351(9098), 233–241.
Ridker, P. M., Cook, N. R., Lee, I. M., Gordon, D., Gaziano, J. M., Manson, J. E., et al. (2005). A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. New England Journal of Medicine, 352(13), 1293–1304.
Ikeda, Y., Shimada, K., Teramoto, T., Uchiyama, S., Yamazaki, T., Oikawa, S., et al. (2014). Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: A randomized clinical trial. JAMA, 312(23), 2510–2520.
ASCEND Study Collaborative Group. (2018). Effects of aspirin for primary prevention in persons with diabetes mellitus. New England Journal of Medicine, 379(16), 1529–1539.
Gaziano, J. M., Brotons, C., Coppolecchia, R., Cricelli, C., Darius, H., Gorelick, P. B., et al. (2018). Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A randomised, double-blind, placebo-controlled trial. Lancet, 392(10152), 1036–1046.
Calonge, N., Petitti, D. B., DeWitt, T. G., Gordis, L., Gregory, K. D., Harris, R., et al. (2009). Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 150(6), 396–404.
Van’t Hof, J. R., Duval, S., Walts, A., Kopecky, S. L., Luepker, R. V., & Hirsch, A. T. (2017). Contemporary primary prevention aspirin use by cardiovascular disease risk: Impact of US Preventive Services Task Force Recommendations, 2007–2015: A Serial, Cross-sectional Study. Journal of the American Heart Association, 6(10), e006328.
Shahar, E., Folsom, A. R., Romm, F. J., Bisgard, K. M., Metcalf, P. A., Crum, L., et al. (1996). Patterns of aspirin use in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. American Heart Journal, 131(5), 915–922.
Rodondi, N., Vittinghoff, E., Cornuz, J., Butler, J., Ding, J., Satterfield, S., et al. (2005). Aspirin use for the primary prevention of coronary heart disease in older adults. The American Journal of Medicine, 118(11), 1281–1288.
Glasser, S. P., Cushman, M., Prineas, R., Kleindorfer, D., Prince, V., You, Z., et al. (2008). Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)? Preventive Medicine, 47(2), 161–166.
Sanchez, D. R., Roux, A. V. D., Michos, E. D., Blumenthal, R. S., Schreiner, P. J., Burke, G. L., & Watson, K. (2011). Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis. The American Journal of Cardiology, 107(1), 41–46.
Johansen, M. E., Hefner, J. L., & Foraker, R. E. (2015). Antiplatelet and statin use in US patients with coronary artery disease categorized by race/ethnicity and gender, 2003 to 2012. The American Journal of Cardiology, 115(11), 1507–1512.
Fang, J., George, M. G., Gindi, R. M., Hong, Y., Yang, Q., Ayala, C., et al. (2015). Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012). The American Journal of Cardiology, 115(7), 895–900.
Winter, S. J., Sheats, J. L., & King, A. C. (2016). The use of behavior change techniques and theory in technologies for cardiovascular disease prevention and treatment in adults: A comprehensive review. Progress in Cardiovascular Diseases, 58(6), 605–612.
Plotnikoff, R. C., Lubans, D. R., Costigan, S. A., & McCargar, L. (2013). A test of the theory of planned behavior to predict physical activity in an overweight/obese population sample of adolescents from Alberta, Canada. Health Education & Behavior, 40(4), 415–425.
Norman, P., Conner, M., & Bell, R. (1999). The theory of planned behavior and smoking cessation. Health Psychology, 18(1), 89–94.
Lin, C. Y., Broström, A., Nilsen, P., & Pakpour, A. H. (2018). Using extended theory of planned behavior to understand aspirin adherence in pregnant women. Pregnancy Hypertension, 12, 84–89.
Ajzen, I. (1991). The theory of planned behavior. Organizational Behavior and Human Decision Processes, 50(2), 179–211.
Brown, D. W., Shepard, D., Giles, W. H., Greenlund, K. J., & Croft, J. B. (2005). Racial differences in the use of aspirin: An important tool for preventing heart disease and stroke. Ethnicity & Disease, 15(4), 620–626.
Gu, Q., Dillon, C. F., Eberhardt, M. S., Wright, J. D., & Burt, V. L. (2015). Preventive aspirin and other antiplatelet medication use among US adults aged ≥ 40 years: Data from the National Health and Nutrition Examination Survey, 2011–2012. Public Health Reports, 130(6), 643–654.
Karmali, K. N., Goff, D. C., Ning, H., & Lloyd-Jones, D. M. (2014). A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. Journal of the American College of Cardiology, 64(10), 959–968.
Williams, C. D., Chan, A. T., Elman, M. R., Kristensen, A. H., Miser, W. F., Pignone, M. P., et al. (2015). Aspirin use among adults in the US: Results of a national survey. American Journal of Preventive Medicine, 48(5), 501–508.
Halbert, C. H., Armstrong, K., Gandy, O. H., & Shaker, L. (2006). Racial differences in trust in health care providers. Archives of Internal Medicine, 166(8), 896–901.
Victor, R. G., Lynch, K., Li, N., Blyler, C., Muhammad, E., Handler, J., et al. (2018). A cluster-randomized trial of blood-pressure reduction in black barbershops. New England Journal of Medicine, 378(14), 1291–1301.
Zantek, N. D., Luepker, R. V., Duval, S., Miller, K., Oldenburg, N., & Hirsch, A. T. (2014). Confirmation of reported aspirin use in community studies: Utility of serum thromboxane B2 measurement. Clinical and Applied Thrombosis/Hemostasis, 20(4), 385–392.
This study was funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, Grant No. R01HL126041.
Conflict of interest
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Van’t Hof, J.R., Duval, S., Misialek, J.R. et al. Aspirin Use for Cardiovascular Disease Prevention in an African American Population: Prevalence and Associations with Health Behavior Beliefs. J Community Health 44, 561–568 (2019). https://doi.org/10.1007/s10900-019-00646-5
- Cardiovascular disease
- African Americans
- Health behavior